Wegovy 7.2 mg
A higher-dose option above the standard 2.4 mg maintenance — designed for patients who need additional weight loss after the standard ceiling.
For most of Wegovy's life on the U.S. market, 2.4 mg once weekly was the ceiling. That was the dose that earned the FDA's 2021 weight-management approval and the dose used in the STEP 1 trial. In 2025, Novo Nordisk's label expansion introduced a higher dose: 7.2 mg once weekly.
The 7.2 mg dose isn't where you start. It's where some patients escalate after at least four weeks of maintaining the standard 2.4 mg dose, when additional weight loss is the goal and tolerability allows. For super-responders and for patients whose progress has plateaued, the higher dose is now a documented option rather than off-label improvisation.
If your prescriber has mentioned 7.2 mg as a possibility, here is the practical picture: who it is for, how the trial data looks, and the trade-offs that come with stepping up.
What it is
Wegovy 7.2 mg is the same semaglutide molecule used in the standard 2.4 mg dose. It comes in a pre-filled, once-weekly pen with a higher concentration. The injection technique, the dosing day, and the subcutaneous route are unchanged.
The titration path to 7.2 mg starts the same way every Wegovy course does: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over roughly 16 to 20 weeks. Patients who stay at 2.4 mg for at least four weeks, who tolerate it well, and who want additional weight loss can then be considered for stepping up to 7.2 mg. The exact escalation pace is set by the prescriber.
The mechanism doesn't change. Wegovy 7.2 mg works the same way as 2.4 mg — selective GLP-1 receptor agonism, slower gastric emptying, blunted appetite, improved glycemic handling. What changes is the magnitude of those effects, and the magnitude of the side effects that come with them.
How it compares
Compared with standard Wegovy 2.4 mg, the high dose produces additional mean weight loss in trial extension data, with a larger fraction of patients reaching very high responder thresholds (greater than 20 to 25 percent body weight loss). For patients who have already maxed out 2.4 mg, the 7.2 mg dose offers headroom that previously did not exist within the Wegovy label.
Compared with Zepbound (tirzepatide 15 mg), the 7.2 mg dose narrows the head-to-head gap that SURMOUNT-5 and prior trials documented at standard doses. Whether high-dose Wegovy fully closes that gap is a question the comparative data is still answering; at minimum, it gives semaglutide patients a longer ladder before switching to a different drug class.
Side effects scale with dose. Patients who barely tolerated 2.4 mg are not the right candidates for 7.2 mg. Nausea, constipation, fatigue, and reflux often intensify when stepping up. The dose ceiling for any individual patient is the highest dose they can sustain on a routine schedule, not the highest dose the label allows.
What to know if you're considering it
Stepping up to Wegovy 7.2 mg
Stable on 2.4 first
Most prescribers want at least four weeks of stable 2.4 mg with manageable side effects before considering 7.2 mg. Rushing the step is the fastest way to derail tolerance.
Re-watch side effects
Nausea, reflux, and bowel changes that resolved at 2.4 mg can return when you escalate. Plan for a second titration period at the higher dose.
Talk about the goal
7.2 mg is for additional weight loss after a plateau. If you're already meeting your goals on 2.4 mg, the higher dose isn't usually the right move.
Common questions
Common Concerns
Is Wegovy 7.2 mg where everyone ends up?expand_more
How much more weight will I lose at 7.2 mg?expand_more
Will the side effects get worse?expand_more
Will insurance cover 7.2 mg?expand_more
Keep exploring
Browse all GLP-1 guides.